Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits

Nature Reviews Cancer

Volumn 9, Issue 4, 2009, Pages 265-273

  Polyak, Kornelia ^a   Weinberg, Robert A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNTRANSLATED RNA;

CANCER STEM CELL; CELL INTERACTION; EPIGENETICS; EPITHELIUM CELL; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; MESENCHYMAL STEM CELL; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA CELL;

ANIMALS; EPIGENESIS, GENETIC; EPITHELIAL CELLS; HUMANS; MESODERM; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 63049123066     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2620     Document Type: Review

References (87)

1. Baum, B., Settleman, J. & Quinlan, M. P. Transitions between epithelial and mesenchymal states in development and disease. Semin. Cell Dev. Biol. 19, 294-308 (2008).
2. Hugo, H. et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell Physiol. 213, 374-383 (2007).
3. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Rev. Mol. Cell Biol. 7, 131-142 (2006).
4. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
5. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008). This manuscript is the first demonstration that EMT leads to the generation of breast cancer cells with stem cell-like characteristics.
6. Morel, A. P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3, e2888 (2008).
7. Sabbah, M. et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 11, 123-151 (2008).
8. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Rev. Cancer 7, 415-428 (2007).
9. Dumont, N. et al. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl Acad. Sci. USA 105, 14867-14872 (2008).
10. Massague, J. TGFβ in cancer. Cell 134, 215-230 (2008).
11. James, D., Levine, A. J., Besser, D. & Hemmati-Brivanlou, A. TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132, 1273-1282 (2005).
12. Ozdamar, B. et al. Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity. Science 307, 1603-1609 (2005).
13. Vincan, E. & Barker, N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin. Exp. Metastasis 25, 657-663 (2008).
14. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
15. Lombaerts, M. et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 94, 661-671 (2006).
16. Onder, T. T. et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68, 3645-3654 (2008).
17. Zhang, W. et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 68, 2764-2772 (2008).
18. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genet. 36, 417-422 (2004).
19. Caldwell, G. M. et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64, 883-888 (2004).
20. Aguilera, O. et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116-4121 (2006).
21. Bailey, J. M., Singh, P. K. & Hollingsworth, M. A. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J. Cell Biochem. 102, 829-839 (2007).
22. Wang, Z. et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66, 2778-2784 (2006).
23. Gort, E. H., Groot, A. J., van der Wall, E., van Diest, P. J. & Vooijs, M. A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr. Mol. Med. 8, 60-67 (2008).
24. Cannito, S. et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29, 2267-2278 (2008).
25. Sahlgren, C., Gustafsson, M. V., Jin, S., Poellinger, L. & Lendahl, U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl Acad. Sci. USA 105, 6392-6397 (2008).
26. Radisky, D. C. et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127 (2005). This study is the first to establish a link between EMT and reactive oxygen species generation and subsequent genomic instability.
27. Brabletz, T. et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl Acad. Sci. USA 98, 10356-10361 (2001).
28. Franci, C. et al. Expression of Snail protein in tumor-stroma interface. Oncogene 25, 5134-5144 (2006). This is the first report describing EMT in physiological in vivo conditions in tumours.
29. Sheehan, K. M. et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 27, 323-331 (2008).
30. Yates, C. C., Shepard, C. R., Stolz, D. B. & Wells, A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br. J. Cancer 96, 1246-1252 (2007).
31. Frisch, S. M. The epithelial cell default-phenotype hypothesis and its implications for cancer. Bioessays 19, 705-709 (1997).
32. Chaffer, C. L., Thompson, E. W. & Williams, E. D. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185, 7-19 (2007).
33. Bloushtain-Qimron, N. et al. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl Acad. Sci. USA 105, 14076-14081 (2008). The first comprehensive characterization of cell type-specific DNA methylation patterns of normal breast progenitor cells and identification of epigenetically regulated transcription factors, including FOXC1, as regulators of stem cell properties.
34. - breast cancer cells and identification of the TGFβ signalling pathway as a candidate regulator of their stem cell-like phenotype.
35. Dunbier, A. & Guilford, P. Hereditary diffuse gastric cancer. Adv. Cancer Res. 83, 55-65 (2001).
36. Schrader, K. A. et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam. Cancer 7, 73-82 (2008).
37. Berx, G. et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13, 1919-1925 (1996).
38. Ateeq, B., Unterberger, A., Szyf, M. & Rabbani, S. A. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10, 266-278 (2008).
39. Guo, Y. et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J. Biol. Chem. 277, 41571-41579 (2002).
40. Moreno-Bueno, G., Portillo, F. & Cano, A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27, 6958-6969 (2008).
41. Ansieau, S. et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14, 79-89 (2008). An important study demonstrating a dual role for EMT-inducing transcription factors in tumorigenesis and senescence.
42. Perez-Losada, J. et al. Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood 100, 1274-1286 (2002).
43. Sanchez-Martin, M. et al. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum. Mol. Genet. 11, 3231-3236 (2002).
44. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biol. 10, 593-601 (2008).
45. Gregory, P. A., Bracken, C. P., Bert, A. G. & Goodall, G. J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7, 3112-3118 (2008).
46. Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008). An important study describing the regulation of EMT-inducing transcription factors by miRNAs.
47. Beltran, M. et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 22, 756-769 (2008). An interesting study identifying a novel mechanism for the regulation of EMT through the expression of a natural antisense RNA suppressing ZEB2 expression.
48. Cano, A. & Nieto, M. A. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol. 18, 357-359 (2008).
49. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007). The first study demonstrating a role for miRNAs in breast cancer metastasis.
50. Tavazoie, S. F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152 (2008).
51. Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007).
52. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 8, R59 (2006).
53. Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B. & Herman, J. G. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275, 2727-2732 (2000).
54. Nass, S. J. et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60, 4346-4348 (2000).
55. Riethdorf, S. & Pantel, K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 75, 140-148 (2008).
56. Riethdorf, S., Wikman, H. & Pantel, K. Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 123, 1991-2006 (2008).
57. Slade, M. J. et al. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br. J. Cancer 100, 160-166 (2008).
58. Sarrio, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68, 989-997 (2008).
59. Mani, S. A. et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl Acad. Sci. USA 104, 10069-10074 (2007).
60. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
61. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
62. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10, R53 (2008).
63. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
64. Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
65. Barr, S. et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin. Exp. Metastasis 25, 685-693 (2008).
66. Robson, E. J., Khaled, W. T., Abell, K. & Watson, C. J. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 74, 254-264 (2006).
67. Muerkoster, S. S. et al. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma - epigenetic downregulation of caspases. Int. J. Cancer 123, 1751-1760 (2008).
68. 2 availability on human cancer. Nature Rev. Cancer 8, 967-975 (2008).
69. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
70. Norton, L. & Massague, J. Is cancer a disease of self-seeding? Nature Med. 12, 875-878 (2006).
71. Jones, P. A. & Takai, D. The role of DNA methylation in mammalian epigenetics. Science 293, 1068-1070 (2001).
72. Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143-153 (2004).
73. Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
74. Futscher, B. W. et al. Role for DNA methylation in the control of cell type specific maspin expression. Nature Genet. 31, 175-179 (2002).
75. Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nature Rev. Genet. 7, 21-33 (2006).
76. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer-mechanims for early oncogenic pathway addiction? Nature Rev. Cancer 6, 107-116 (2006).
77. Holm, T. M. et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8, 275-285 (2005).
78. Plass, C. Cancer epigenomics. Hum. Mol. Genet. 11, 2479-2488 (2002).
79. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
80. Stefani, G. & Slack, F. J. Small non-coding RNAs in animal development. Nature Rev. Mol. Cell Biol. 9, 219-230 (2008).
81. Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Rev. Genet. 9, 102-114 (2008).
82. Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A. & Croce, C. M. MicroRNA expression and function in cancer. Trends Mol. Med. 12, 580-587 (2006).
83. Come, C. et al. Snail and slug play distinct roles during breast carcinoma progression. Clin. Cancer Res. 12, 5395-5402 (2006).
84. Aigner, K. et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 581, 1617-1624 (2007).
85. Zhou, B. P. et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biol. 6, 931-940 (2004).
86. Martin, T. A., Goyal, A., Watkins, G. & Jiang, W. G. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 12, 488-496 (2005).
87. Elloul, S. et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103, 1631-1643 (2005).